Looking Beyond Hepatitis C: Here's How Gilead Could Make Another $10 Billion Annually

Looking Beyond Hepatitis C: Here's How Gilead Could Make Another $10 Billion Annually


Blame it on a number of factors -- competition, price discounts to expand the patient pool, a changing mix of payers -- but the fact of the matter is that Gilead's top line is falling for the first time in years. Fortunately, the embattled big-cap biotech has two big opportunities to reignite growth -- to the tune of $10 billion in revenue or more.



from Biotech News